Biotech ‘Cambrian Explosion’ Could Be THE Stock Story of 2019

By ,

Yesterday, I teased a slowly-brewing trend on the fringes of biotech. If you’re into speculative investing, you should try and get your head around this trend now.

It’s to do with blockchain and genomics. And it’s getting very little attention at the moment. From mainstream press…and from investors.

The stocks propelling this trend are still in the embryonic stages. Much like the companies pioneering genomic medicine in 2003 and 2004.

In the 15 years since, the cream of those stocks have soared to the moon.

(Illumina 28,198%; NeoGenomics 5,600%; Bluebird Bio 1,115%; Celgene 27,650%; Shire PLC 1,400% and many more…)

A decade-and-a-half after the Human Genome Project, genomic medicine is about to experience another great leap forward. The driving engine of this next phase is blockchain.

And the potential gains for those who make the effort to understand this trend could be absolutely enormous.

If there was a fuss about blockchain-driven cryptocurrencies last year, wait until you see what happens in this space over the next five to 10 years.

But, as I say, this is very early stage stuff.

Hardly anyone, anywhere (that I’ve seen, anyway) is doing this research, joining the dots, and studying the small and micro-cap companies I’ve been following this year, who are quietly working to become future leaders in ‘blockchain genomics’.

That’s why I’ve decided to share my findings with you this week…


The new ‘Cambrian Explosion’ brought about by blockchain and biotech

For most of the 4 billion-odd years life has existed on Earth, there was little that qualified as life as we’d recognise it.

It was mostly bacteria, plankton and algae.

Primordial sludge.

The wheels of evolution seemed to have ground to a halt in a gooey end.

Then suddenly, between 530 and 570 million years ago, there was a burst of change.

A stunning and rapid period of evolutionary flowering resulting in the appearance of the lineage of almost all animals living today.

It’s a unique period of time known as the ‘Cambrian Explosion.’

Without it, we’d still be living in Sludge-ville.

So how did it happen?



No one quite agrees on why this period was so prolific in creating new forms of life.

Some scientists point to an increase in oxygen in the atmosphere. The theory is this resulted in more fuel for movement and the allowance of more complex body types.

Others think it was a crucial change at the genetic level.

The formation of a ‘genetic tool kit’ as it were, that suddenly gave evolution a free hand in trying out a multitude of weird experiments.

I’m not talking the slow Darwinian process of small, incremental changes here.

No, this was a blank canvas trying out a whole host of different things.

Of course, only those that evolved to survive are still with us. Many species died out without a trace.

But the point is this…


It was a pivotal moment in Earth’s history

Without it, you and I wouldn’t be here today.

And it was likely due to the addition of just one new element.

The evolutionary straw that broke the camel’s back, so to speak.

Those who’ve read my stock research know that one of my focuses when looking for stocks that could return gains on an exponential scale, will know that I focus on ‘collision points’.

Points where certain trends and technologies collide to create ‘exponential’ progress. And exponential stock gains — if you pick the stocks that will drive this progress in the future, while they are still relatively unknown.

The great collision of microchips and computers is a great example.

It happened when the microchip was invented in 1959. This gave us Moore’s Law; meaning that from there until 2012 the speed and power of computers began to double every two years.

This collision, in turn, created the consumer electronics boom.

And if you were an early mover on the companies that ‘spun off’ from this collision, you could have made dynasty-creating, almost hallucinatory wealth.


IBM 9,456,410%
Intel 119,590%
Microsoft 83,440%
General Electric 922,170%
Apple 22,250%


Now, back to the Cambrian Explosion.

This was one of the first great collision points. At least here on Earth (The big bang probably takes the ultimate honours).


I believe we are approaching a similar scale ‘collision point’ in medicine

Its potential to alter the very course of humanity…and even evolution itself…cannot be overstated.

I mean it.

This is THAT big.

It is, in the words of one of the technologists driving this collision, going to usher in ‘an unprecedented era of medical marvels.’

It is, in my own view, potentially more impactful on how we live than the Cambrian Explosion in electronics in the 1960s.

And, potentially, even more profitable if you pick the future blue chips while they’re still babies.

Now, that’s some claim, I know.

Pretty audacious.

Very easy to brush off.

Which is why I want you to stick with me and read tomorrow’s edition very carefully.

Because I’m going to show you more of my research into this. And I think it’s going to blow your mind.

We’re going to be looking in more depth at the collision of blockchain technology into biotech. And a small clutch of unknown stocks that I believe could be the main beneficiaries of this trend.

They’re all involved in some way — either directly or indirectly — with the SECOND, under-the-radar ‘Great Genomic Project’ of the 21st Century.

It’s aimed at bringing the power of blockchain to the world of genomics.

If it lives up to even half its promise it could alter medicine at a genetic level. And send certain stocks into the stratosphere.

In fact, these stock performances could match…or even OUTPACE…the very best technology stocks born in the 1960s and 1970s…and the very best spin-off stocks from the Human Genome Project.

I’m talking potential multiples of 50, 100 or even 200 times earnings here.

Over the next few days I’m going to demonstrate why this is the case. We’ll talk more about the intersection of blockchain and genomics. And, next week, we’ll start talking stocks. Four stocks in particular…


Until tomorrow,

Ryan Dinse,
Editor, Exponential Stock Investor

About Ryan Dinse

Ryan Dinse is an Editor at Money Morning.

He has worked in finance and investing for the past two decades as a financial planner, senior credit analyst, equity trader and fintech entrepreneur.

With an academic background in economics, he believes that the key to making good investments is investing appropriately…

Renascor (ASX:RNU) Shares Rise on Highest-Grade Graphite to Date

South Australian graphite stock Renascor Resources [ASX:RNU] released drilling assay results showing its ‘highest grade graphite to date’.

Talga [ASX:TLG] Shares Rise on Vittangi Graphite Drilling Update

Graphite and battery materials stock Talga Group Ltd [ASX:TLG] updated the market on new drill results at its Sweden graphite project.

Bubs Announces $68 Million Capital Raise

[ASX:BUB] is rattling the can to raise $68 million to support ‘growth opportunities.’

Is Stock Analysis Worth It? Finding Your Investment Edge

Is stock analysis worth your time? The question boils down to a key academic topic: market efficiency.

Bubs (ASX:BUB) Shares up on US Supply Deal Update

Infant nutrition producer Bubs Australia [ASX:BUB] came out with another supplier update today, signing supply agreements with two more US retailers.

NeuRizer [ASX:NRZ] Shares Soar on $1.5 Billion Binding Offtake

NeuRizer [ASX:NRZ] opened 35% higher on Monday after announcing a binding $1.5 billion offtake agreement with Daelim.